トップページ > NEWS > ESMO2025にて研究内容の発表を行います（10月17日-21日）
ESMO2025にて研究内容の発表を行います（10月17日-21日）
2025年10月2日
当院では、ESMO2025（欧州臨床腫瘍学会）にて、以下の研究内容について発表いたします。
- 日時：2025年10月17日-21日
- 場所：ドイツ・ベルリン（Messe Berlin）
- 学会名：European Society For Medical Oncology（ESMO）https://www.esmo.org/（外部サイトにリンクします）
| 診療科 | 演題番号 | 筆頭演者 | 演題名 |
| 肝胆膵外科 | 768P | Shin Kobayashi | Survival and benefit of adjuvant chemotherapy (ACT) by circulating tumor DNA (ctDNA)-based pretreatment genomic profile and postoperative molecular residual disease (MRD) in resectable colorectal oligometastases (CRM): PRECISION, a prospective multicenter study |
| 消化管内科 | 2137P | Kohei Shitara | ASP2138 Monotherapy in Patients (Pts) With Claudin 18 Isoform 2 (CLDN18.2)+, Advanced Solid Tumors: Phase 1 / 1b Trial |
| 消化管内科 | 738P | Yuki Matsubara | Impact of prior anti-EGFR therapy (EGFRi) on efficacy of pertuzumab (PER) plus trastuzumab (TRA) for HER2-positive (HER2+) metastatic colorectal cancer (mCRC): TRIUMPH/MyPathway integrated analysis |
| 消化管内科/医薬品開発推進部門 | 825P | Kazumasa Yamamoto | Chronological Changes in Clinical Outcomes of Standard First-Line Oxaliplatin-Based Chemotherapy + Targeted Agents for Metastatic Colorectal Cancer: Updated Analysis of the ARCAD Database |
| 肝胆膵内科 | 1728P | Hiroshi Imaoka | Initial Experience with 177Lu-DOTATATE in Patients with Neuroendocrine Neoplasms: A Multicenter Retrospective Study in Japan |
| 医薬品開発推進部門 | 767P | Tadayoshi Hashimoto | Analysis of baseline alterations and ctDNA to predict colorectal cancer recurrence |
| 医薬品開発推進部門 | 115MO | Hideaki Bando | Comprehensive Multi-Omics Analysis of Early-Onset Cancer: Insights from the MONSTAR-SCREEN-2 Experience |
| 医薬品開発推進部門 | 734MO | Yoshiaki Nakamura | Performance of a blood-based, early cancer detection (ECD) screening test for colorectal cancer (CRC) in cell-free (cf)DNA |
| 医薬品開発推進部門 | 738P | Yuki Matsubara | Impact of prior anti-EGFR therapy (EGFRi) on efficacy of pertuzumab (PER) plus trastuzumab (TRA) for HER2-positive (HER2+) metastatic colorectal cancer (mCRC): TRIUMPH/MyPathway integrated analysis |
| 医薬品開発推進部門 | 777P | Hideaki Bando | Spatial transcriptomic dynamics of the tumor microenvironment after chemoradiotherapy followed by immune checkpoint blockade in locally advanced rectal cancer: A translational study from VOLTAGE trial |
| 医薬品開発推進部門 | 172TiP | Mitsuho Imai | Spatial transcriptomics-driven tumor microenvironment profiling in the MONSTAR-3 prospective multi-institutional study |
| 医薬品開発推進部門 | 808P | Mitsuho Imai | Spatial Transcriptomics (ST) Reveals Tumor Microenvironment (TME) Heterogeneity and Resistance Mechanisms to HER2 Inhibition in HER2-positive (HER2+) Metastatic Colorectal Cancer (CRC) |
| 腫瘍内科 | 617TiP | Mafalda Oliveira(co-author:Toru Mukohara) | Randomized phase 3 trial evaluating KAT6 inhibitor PF-07248144 plus fulvestrant in HR+/HER2–advanced/metastatic breast cancer after progression on CDK4 / 6 inhibitor-based therapy. |
| 腫瘍内科 | Special symposium | Kenichi Harano | How to treat ovarian cancer patients post PARPi therapy? 「Novel immunotherapy」 |
| 腫瘍内科 | 2856P | Chikako Funasaka | Exploratory analysis of the Control trial to validatE mitigation of Chemotherapy-Induced peripheral neuropathy (CIPN) by LImb-cooling Apparatus in breast cancer patients receiving weekly paclitaxel (CECILIA) |
| 腫瘍内科 | 1135P | Misao Fukuda | Differential Expression of Key Therapeutic Target Proteins Across Ovarian Cancer Histologic Subtypes |
| 呼吸器内科 | 2002P | Haruka Nakatani | Clinical, pathological and genomic features and therapeutic outcomes of non-small cell lung cancer with HER2 amplification |
| 呼吸器内科 | 1912P | Zenke Yoshitaka | Inflamed immune phenotype as a novel predictive marker of immune checkpoint inhibitors for non-small cell lung cancer |
| 呼吸器内科 | 1930P | Shingo Kitagawa | A ctDNA-derived tumor DNA methylation score as a predictive biomarker of treatment response in advanced non-small cell lung cancer: LC-SCRUM-MRD |
| 呼吸器内科 | 2006P | Hiroki Izumi | Conducive multi-level screening of genetic and protein aberrations in non-small cell lung cancer: A report from LC-SCRUM-Asia |
| 薬剤部 | 402P | Shota Uesawa | CITRUS: Prospective study of Chemotherapy-Induced Taste alteRation and qUality of life Survey in patients with breast cancer |